(Q38725208)

5 September 2017

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma (English)

1 reference

5 September 2017

0 references

1 reference

Jake Shortt

2

0 references

Ricky W Johnstone

object named as

Ricky Johnstone

series ordinal

3

0 references

author name string

Jonathan D Licht

series ordinal

1

1 reference

PMC publication ID

3984916

5 September 2017

language of work or name

1 reference

1 January 2014

1 reference

5 September 2017

1 reference

5 September 2017

25

1 reference

5 September 2017

1

1 reference

5 September 2017

9-11

1 reference

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

5 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Identification of a primary target of thalidomide teratogenicity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Antitumor activity of thalidomide in refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3984916

10.1016/J.CCR.2013.12.019

31 August 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference

PMC publication ID

3984916

5 September 2017

PubMed publication ID

24434206

1 reference

PMC publication ID

3984916